Financials Positive

2026-05-30 19:11

Jeena Sikho Lifecare Limited's Board of Directors approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, with an unmodified audit opinion. The Board also recommended a final dividend of Rs. 4.50 per equity share (face value Rs. 2/-) for the financial year 2025-26 and re-appointed M/s Forvis Mazars LLP as the Internal Auditor for FY 2026-27.

Financials Positive

2026-05-30 19:05

The Board of Directors of Jeena Sikho Lifecare Limited, in its meeting on May 30, 2026, approved the Audited Standalone and Consolidated Financial Results for the quarter and financial year ended March 31, 2026, with an unmodified audit opinion. The board also recommended a final dividend of Rs. 4.50 per equity share for the financial year 2025-26. M/s Forvis Mazars LLP was re-appointed as the internal auditor.

Financials Positive

2026-05-30 19:05

The Board of Directors of Jeena Sikho Lifecare Limited approved the Audited Standalone and Consolidated Financial Results for the quarter and financial year ended March 31, 2026, with an unmodified audit opinion. The board recommended a final dividend of Rs. 4.50 per equity share for the financial year 2025-26, subject to shareholder approval. M/s Forvis Mazars LLP was re-appointed as the Internal Auditor for FY 2026-27.

Financials Positive

2026-05-30 18:59

Consolidated Revenue ₹215.55 Cr vs ₹139.25 Cr (▲54.79% YoY), EBITDA ₹77.92 Cr vs ₹45.77 Cr (▲70.24% YoY), PAT ₹45.08 Cr vs ₹25.34 Cr (▲77.81% YoY). EBITDA Margin 36.15% vs 32.87% (▲328bps). The board also recommended a final dividend of Rs. 4.50/- per equity share for FY 2025-26 and re-appointed M/s Forvis Mazars LLP as internal auditor.

Financials Positive

2026-05-30 18:20

The Board of Directors approved the Audited Consolidated Financial Results for the quarter and financial year ended March 31, 2026. Consolidated Revenue was ₹215.55Cr vs ₹139.25Cr (▲54.79% YoY), EBITDA was ₹77.92Cr vs ₹45.77Cr (▲70.25% YoY), and PAT was ₹45.08Cr vs ₹25.34Cr (▲77.89% YoY). EBITDA Margin expanded from 32.87% to 36.15% (▲328bps). The board also recommended a final dividend of ₹4.50 per equity share for the financial year 2025-26.

Governance Negative

2026-05-30 14:21

CRITICAL RED FLAG DETECTED

Jeena Sikho Lifecare Limited filed its Annual Secretarial Compliance Report for FY2026. The report noted a fine of ₹11,800 levied by BSE and NSE for delayed intimation of Q2 FY2026 Board Meetings, which the company paid and addressed. Statutory auditors, M/s KRA & Co., resigned effective August 14, 2025, due to the company's migration to the Main Board, with M/s Walker Chandiok & Co LLP subsequently appointed, adhering to SEBI regulations.

Business Update Neutral

2026-05-27 17:58

Jeena Sikho Lifecare Limited will host an Earnings Conference Call for investors and analysts to discuss the Audited Financial Results for Q4 FY26 and the full financial year ended March 31, 2026. The call is scheduled for Tuesday, June 02, 2026, at 01:30 P.M. IST, with participation from Mr. Manish Grover (Managing Director) and Mr. Nanak Chand (Chief Financial Officer).

Business Update Positive

2026-05-25 19:17

Jeena Sikho Lifecare Limited announced the publication of multiple case studies and case reports authored by medical professionals associated with the company, including its Managing Director. These publications, featured in various international journals, highlight the company's ongoing commitment to Ayurvedic research and evidence-based clinical practice across conditions such as chronic kidney disease, hypertension, ovarian cysts, and liver cirrhosis.

Financials Neutral

2026-05-21 15:32

Jeena Sikho Lifecare Limited announced that a Board Meeting will be held on Saturday, May 30, 2026, to consider and approve the Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended March 31, 2026. The board will also consider and recommend a Final Dividend, if any, for the financial year 2025-26. The trading window for designated persons remains closed until 48 hours after the results declaration.

Governance Neutral

2026-05-21 15:27

Jeena Sikho Lifecare Limited announced that its Board of Directors will meet on May 30, 2026, to consider and approve the Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended March 31, 2026. The Board will also consider and recommend a Final Dividend for FY 2025-26. The trading window for designated persons remains closed from April 1, 2026, until 48 hours post results declaration.

Business Update Positive

2026-05-09 18:41

Jeena Sikho Lifecare Limited announced the sale of approximately 48 Bigha of non-operational land situated in Patiala, Punjab, to Tresco Realty Group LLP for an aggregate consideration of ₹24,00,00,000 (Rupees Twenty-Four Crores Only). The Board of Directors approved the sale on May 8, 2026. The company stated that the sale of this non-operational asset will not impact its business operations and it is not a related party transaction.

Business Update Positive

2026-05-08 17:57

Jeena Sikho Lifecare Limited announced the sale of approximately 48 Bigha of non-operational land in Punjab to Tresco Realty Group LLP for an aggregate consideration of ₹24,00,00,000/- (Rupees Twenty-Four Crores Only). The Board approved the sale on May 8, 2026. The company stated that this transaction will not impact its core business operations as the land was non-operational.

Routine Neutral

2026-05-04 20:35

New Filing detected. See link for details.

Business Update Positive

2026-05-04 19:14

Jeena Sikho Lifecare Limited announced on May 4, 2026, the publication of seven case studies and two case reports in the "Journal of Applied Science and Education (JASE)". These were authored by the company's medical professionals, including the Managing Director, senior consultants, and Ayurvedic experts, demonstrating the Company's ongoing commitment to Ayurvedic research and evidence-based clinical practice.

Routine Neutral

2026-04-16 13:33

Jeena Sikho Lifecare Limited has intimated that it does not qualify as a 'Large Corporate' as per SEBI regulations for the financial year ended March 31, 2026, with an outstanding borrowing of ₹0.43 Cr. The company is not subject to the fund-raising requirements for large entities.

Business Update Positive

2026-04-15 17:18

Jeena Sikho Lifecare Limited received NABH Accreditation for its Noida Hospital's Panchakarma services, valid until March 09, 2029. This signifies adherence to nationally recognized standards for quality healthcare delivery and patient safety.

Routine Neutral

2026-04-14 23:35

New Filing detected. See link for details.

Routine Neutral

2026-04-03 14:34

Jeena Sikho Lifecare Limited submitted a Certificate under Regulation 74(5) of SEBI (Depositories and Participants Regulations) 2018, from its RTA, Skyline Financial Services, confirming compliance regarding dematerialization for the quarter and year ended March 31, 2026.

Routine Neutral

2026-03-23 13:29

Jeena Sikho Lifecare Limited announced the closure of its trading window for Designated Persons and their Immediate Relatives from April 01, 2026, until 48 hours after the declaration of the Audited Financial Results for the Quarter and Financial Year ended March 31, 2026.

Business Update Positive

2026-03-23 12:25

Jeena Sikho Lifecare Limited announced the publication of three case studies/reports in the 'International Journal of Advanced Research (IJAR)', demonstrating its commitment to evidence-based Ayurvedic research. Topics include Ayurvedic management of chronic liver disease, kidney disease, and prostatomegaly.

Business Update Neutral

2026-03-17 15:56

Jeena Sikho Lifecare Limited announced an Investor/Analyst Meet on Monday, 23rd March 2026, at Trident, BKC, Mumbai. Managing Director Mr. Manish Grover and Dr. Ish Sharma will meet institutional investors, including Mutual Fund and Private Equity Funds, for a physical group meeting.

Governance Neutral

2026-03-09 12:35

On March 09, 2026, the Board approved amendments to its Code of Fair Disclosure and internal procedures for regulating and monitoring insider trading by designated persons and their relatives, in compliance with SEBI PIT Regulations, 2015.

Business Update Positive

2026-03-06 17:21

Jeena Sikho Lifecare Limited announced an Investor/Analysts Meet on March 11, 2026, at 12:00 Noon (virtual group meeting). Managing Director Mr. Manish Grover, CFO Mr. Nanak Chand, and Dr. Ish Sharma will participate in the Arihant Capital Bharat Connect Conference- Rising Stars 2026.

Business Update Positive

2026-02-23 14:42

Jeena Sikho Lifecare Limited announced on Feb 23, 2026, the publication of five case studies and one case report by medical professionals, including its MD, in reputed journals. These publications highlight the company's commitment to Ayurvedic research and evidence-based clinical practice, covering topics like fatty liver, chronic kidney disease, and diabetes.

Business Update Positive

2026-02-19 13:28

Jeena Sikho Lifecare Limited received NABH Accreditation for its Dehradun Hospital (Panchakarma services), valid until January 5, 2029. This signifies adherence to nationally recognized standards for quality healthcare delivery, patient safety, and operational excellence.

Business Update Positive

2026-02-16 18:52

Jeena Sikho Lifecare Limited announced the establishment of a new 150-bed hospital unit in Ahmedabad, Gujarat, with an estimated investment of ₹1.5 Crore. Commencement is expected within 6 months.

Business Update Positive

2026-02-13 16:49

Transcript of Q3 FY '26 earnings call highlighting strong financial performance. The company reported a 92% YoY increase in operational income to INR221.7 Cr, EBITDA up 240% to INR100.8 Cr with a 45% margin, and PAT increased 405% to INR66.7 Cr.

Business Update Neutral

2026-02-09 19:39

Jeena Sikho Lifecare Limited submitted the audio recording of its Earnings Conference Call held on February 9, 2026. The call discussed financial results for Q3 FY 2025-26 (quarter and nine-months ended Dec 31, 2025) and is accessible on the company's website.

Financials Positive

2026-02-08 14:32

Revenue ₹221.66Cr vs ₹115.69Cr (▲92% YoY), EBITDA ₹100.80Cr vs ₹29.61Cr (▲240% YoY), PAT ₹66.73Cr vs ₹13.21Cr (▲405% YoY). EBITDA Margin 45% vs 26% (▲1988bps).

Financials Positive

2026-02-07 19:26

Consolidated Revenue ₹221.68Cr vs ₹115.69Cr (▲91.6% YoY), EBITDA ₹100.72Cr vs ₹29.61Cr (▲240.2% YoY), PAT ₹66.60Cr vs ₹13.21Cr (▲404.1% YoY). EBITDA Margin 45.44% vs 25.59% (▲1985bps).

Financials Positive

2026-02-07 19:16

Consolidated Revenue ₹221.68Cr vs ₹115.69Cr (▲91.62% YoY), EBITDA ₹100.72Cr vs ₹20.61Cr (▲388.70% YoY), PAT ₹66.60Cr vs ₹13.21Cr (▲404.13% YoY). EBITDA Margin 45.44% vs 17.81% (▲2763bps).

Governance Neutral

2026-02-03 15:28

Board meeting to be held on February 07, 2026, to consider and approve Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2025. Trading window closed from January 01, 2026 to February 09, 2026.

Business Update Positive

2026-01-22 13:22

Jeena Sikho Lifecare Limited announced the publication of a case report in the 'Ayush Journal of Integrative Oncology'. Authored by the MD and other medical professionals, the report details the one-year disease-free resolution of breast cancer recurrence through Ayurveda, demonstrating commitment to evidence-based practices.

Business Update Negative

2026-01-21 19:45

CRITICAL RED FLAG DETECTED

The Board approved an unsecured loan of AED 7.53 million to its wholly-owned subsidiary, Jeena Sikho International LLC, on Jan 21, 2026, at 8.5% interest for 5 years. The company also disclosed paying fines imposed by NSE and BSE for past non-compliance with SEBI regulations.

Ownership Positive

2026-01-16 17:18

Jeena Sikho Lifecare Limited announced the acquisition of a 51% equity stake in Back to Roots Ayurveda by Dr. Shyam LLC, Abu Dhabi, UAE for 1,530,000 Dirhams. The acquisition aims to strengthen their Ayurveda and wellness segment.

Routine Neutral

2026-01-13 13:33

Jeena Sikho Lifecare Limited entered into a Procurement Agreement with Theryco Healthcare Solutions on January 3rd, 2026, to list and sell products on Amazon. The agreement is not a related party transaction.

Routine Neutral

2026-01-12 14:45

Jeena Sikho Lifecare Limited published case studies and a research article in European and International Journals on Ayurvedic management of Type 2 Diabetes and Chronic Kidney Disease. The filing is dated January 12, 2026.

Routine Neutral

2026-01-07 16:16

Jeena Sikho Lifecare published 9 case studies and reports on Ayurvedic treatments in various journals | Dated January 7, 2026.

Routine Neutral

2026-01-05 14:01

Jeena Sikho Lifecare submits Regulation 74(5) certificate | Compliance with SEBI regulations.

544476

JEENA SIKHO LIFECARE LTD

Filing History

Unlock Full History